je.st
news
Tag: ash
New Data Presented at ASH Annual Meeting Enhance Clinical Knowledge...
2014-12-09 06:57:07| Biotech - Topix.net
Alexion Pharmaceuticals, Inc. today announced that researchers presented data that continue to advance the understanding of atypical hemolytic uremic syndrome and paroxysmal nocturnal hemoglobinuria and provide further insight into optimal care for patients with these devastating diseases.
Tags: data
presented
knowledge
meeting
Gov. Pat McCrory bashes Duke Energy's record on coal ash in '60 Minutes' report
2014-12-08 04:44:58| Energy - Topix.net
N.C. Gov. Pat McCrory, who worked for Duke Energy for 29 years, had little good to say about his former employer in an interview with Lesley Stahl of "60 Minutes." N.C. Gov. Pat McCrory continues to distance himself from his former employer, Duke Energy , telling 60 Minutes ' Lesley Stahl that Duke's record is "quite poor" on dealing with coal ash.
Tags: report
gov
minutes
record
Data Investigating KEYTRUDA (pembrolizumab), Mercks Anti-PD-1 Therapy, in Patients with Classical Hodgkin Lymphoma Presented at ASH Annual Meeting
2014-12-06 19:00:00| Merck.com - Corporate News
Dateline City: SAN FRANCISCO Overall Response Rate of 66 Percent Observed in KEYTRUDA-treated Patients Whose Cancer Progressed on Brentuximab Vedotin Phase 2 Study Planned for the First Half of 2015 (KEYNOTE-087) SAN FRANCISCO--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today early study findings demonstrating that KEYTRUDA (pembrolizumab), the companys anti-PD-1 therapy, achieved an overall response rate of 66 percent, as assessed by International Harmonization Project response criteria (n=19/29: 95% CI, 46-82), in transplant-ineligible and failure patients with relapsed/refractory classical Hodgkin Lymphoma (cHL) whose disease progressed on or after treatment with brentuximab vedotin. Language: English Contact: Media:Pamela Eisele, 267-305-3558orClaire Mulhearn, 908-236-1118orInvestor:Joseph Romanelli, 908-740-1986orJustin Holko, 908-740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: data
presented
meeting
annual
Acetylon's Selective HDAC Inhibitors To Be Featured In Multiple Presentations Of Positive Clinical And Preclinical Data At The 56th ASH Annual Meeting And Exposition
2014-12-03 06:58:10| drugdiscoveryonline News Articles
Acetylon Pharmaceuticals, Inc., the leader in the development of selective histone deacetylase (HDAC) inhibitors for enhanced therapeutic outcomes, recently announced that ricolinostat, the Company’s lead selective HDAC6 inhibitor, and selective HDAC1/2 inhibitors will be featured in one oral presentation and five posters at the 56th American Society of Hematology (ASH) Annual Meeting and Exposition, taking place December 6-9, 2014, in San Francisco, CA
Tags: data
featured
multiple
positive
Wisconsin Groundwater Contaminated by Coal Ash, Says Study
2014-11-19 06:00:00| Climate Ark Climate Change & Global Warming Newsfeed
Midwest Energy News: The "beneficial reuse" of coal ash, often touted as a way to keep the material out of landfills, is potentially causing serious contamination of drinking water in southeast Wisconsin and possibly across the state, according to a report released Tuesday by Clean Wisconsin. By classifying coal ash as an industrial byproduct, as report author Tyson Cook says, companies are able to place contaminant-laden coal ash in the ground - as structural fill in and below roads, trails, parking lots, buildings,...
Tags: study
wisconsin
coal
ash
Sites : [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] [48] [49] [50] [51] [52] [53] [54] [55] next »